Zhong Yuan

List of Publications by Year
in descending order

17	682	1040056 9	888059 17
papers	citations	h-index	g-index

17	17	17	1035
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor. Circulation, 2018, 137, 1450-1459.	1.6	194
2	Comparative effectiveness of canagliflozin, SGLT2 inhibitors and nonâ€SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A realâ€world metaâ€analysis of 4 observational databases (OBSERVEâ€4D). Diabetes, Obesity and Metabolism, 2018, 20, 2585-2597.	4.4	164
3	Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodiumâ€glucose coâ€transporterâ€2 inhibitors in the USA: A retrospective cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 582-589.	4.4	108
4	Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. Diabetes Research and Clinical Practice, 2017, 128, 83-90.	2.8	53
5	Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose coâ€transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. Pharmacoepidemiology and Drug Safety, 2019, 28, 1620-1628.	1.9	36
6	Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives. Current Medical Research and Opinion, 2014, 30, 1733-1741.	1.9	27
7	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE. Chest, 2016, 150, 1059-1068.	0.8	24
8	Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study. Endocrinology, Diabetes and Metabolism, 2020, 3, e00096.	2.4	14
9	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. International Journal of Cardiology, 2018, 257, 78-83.	1.7	10
10	Benefit-Risk Evaluation and Decision Making: Some Practical Insights. Therapeutic Innovation and Regulatory Science, 2015, 49, 425-433.	1.6	9
11	Incidence of ischemic stroke or transient ischemic attack in patients with multiple risk factors with or without atrial fibrillation: a retrospective cohort study. Current Medical Research and Opinion, 2015, 31, 1257-1266.	1.9	9
12	Benefitâ€risk assessment: to quantify or not to quantify, that is the question. Pharmacoepidemiology and Drug Safety, 2011, 20, 653-656.	1.9	8
13	Risk Prediction for Ischemic Stroke and Transient Ischemic Attack in Patients Without Atrial Fibrillation: A Retrospective Cohort Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 1721-1731.	1.6	8
14	Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA. Drug Safety, 2021, 44, 479-497.	3.2	7
15	A study protocol for quantifying patient preferences in neuromuscular disorders: a case study of the IMI PREFER Project. Wellcome Open Research, 2020, 5, 253.	1.8	4
16	Real-World Anticoagulant Use and Incidence of Venous Thromboembolism and Major Bleeding in Children. Clinical Therapeutics, 2021, 43, 2074-2087.	2.5	4
17	Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. Current Medical Research and Opinion, 2020, 36, 1117-1124.	1.9	3